Physician profile
Michael Naddaf
NPI 1790527687
$2,869.31
in general payments reported to CMS, 2019-2025
12 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,156 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.31 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $687.76 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Novo Nordisk INC | $494.07 | 2024-2025 | Wegovy |
| Genzyme Corporation | $478.42 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.38 | 2025 | Trulance, Xifaxan |
| Sobi, INC | $223.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.74 | 2025 | |
| Dexcom, INC. | $112.06 | 2024 | Dexcom G7 Gss (161) |
| Abbvie INC. | $110.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.45 | 2025 | |
| Exact Sciences Corporation | $105.00 | 2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.93 | 2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $94.50 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Naddaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.